The results are likely to be more relevant to patients in sub-Saharan Africa than to those in high-resource settings, the authors say.

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

The second-line use of CDK4/6 inhibitors in advanced breast cancer saves substantial costs while maintaining health outcomes ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...

When allergy season peaks, pediatric ophthalmologists can face a rapid rise in vernal keratoconjunctivitis cases, but it may be difficult to access an approved treatment.

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost ...

To improve the nation’s health and restore the trust that is vital to the doctor-patient relationship, physicians will need to radically shift how they provide medical care,” Pearl ...

Healthcare can be a tricky topic. We all know it’s essential, but the quality of care can vary wildly depending on where you live. Have you ever wondered which countries offer the best healthcare ...

Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...

Tiziana Life Sciences is a buy due to its platform optionality and upcoming catalysts that outweigh its dilution risk and ...